Introduction
HIV-1 can invade the central nervous system (CNS) early during the acute phase of the infection (Davis et al., 1992) 
via virusinfected leukocytes (mostly monocytes and CD4
þ T cells) and/or circulating cell-free virions (Kolb et al., 1999; Wu et al., 2000) . Once in the CNS, the virus can productively infect several residing cell types such as perivascular macrophages, microglial cells and to some extent astrocytes (Anthony and Bell, 2008; Vincendeau et al., 2010) . Since the introduction of the highly active antiretroviral therapy, the incidence of severe neurologic disorders such as HIV-1-associated dementia has dropped drastically. However, patients continue to show some CNS dysfunctions known as minor cognitive motor disorder (Gonzalez-Scarano and Martin-Garcia, 2005) . More recently, a high prevalence of peripheral neuropathy has been noted in HIV-1-infected individuals as well as a persistence of neurological complications better known as HIV-1-associated neurocognitive disorders (HAND) (Crossley and Brew, 2013 ). An overall prevalence of HAND in patients with suppressed plasma viraemia was found to reach 52% in the CHAPTER study (Cysique and Brew, 2011) . A strong correlation between HIV-1-associated neurocognitive disorders and neuroinflammation in infected individuals has been demonstrated (Adle-Biassette et al., 1999) , possibly more so than with the viral load found in the CNS (Gannon et al., 2011) . Elevated concentrations of bacterial lipopolysaccharide, cytokines, viral proteins and eicosanoids present in the plasma of infected individuals have been reported to increase the permeability of the blood-brain barrier (BBB) (Strazza et al., 2011; Vincendeau et al., 2010; Wang et al., 2008) . Furthermore, in the context of HIV-1 encephalitis, a marked augmentation in matrix metalloproteinases (MMPs) produced by astrocytes can be correlated with the disruption of the BBB (Eugenin et al., 2006; Gramegna et al., 2011) . Moreover, certain chemokines produced in the CNS enhance neuroinflammation (such as IP-10, CCL2, MIP-1, CX3CL1 and IL-8) and may promote HIV-1 neuroinvasion by attracting virus-infected leukocytes to this immunologically privileged site (Becker, 2007; Clay et al., 2007; Gesser et al., 1996; Kolb et al., 1999) . Leukotrienes (LTs) are potent proinflammatory lipid mediators that display strong autocrine/paracrine activities and these are produced by innate immune cells when challenged by a pathogenic agent. In stimulated cells, 5-lipoxygenase (5-LO) metabolizes arachidonic acid into either leukotriene B 4 (LTB 4 ) or cysteinylleukotrienes (cysLTs) which include LTC 4 , LTD 4 and LTE 4 . Once secreted, LTB 4 can engage BLT1 or BLT2 receptor, whereas cysLTs exert their effect on receptors such as cysLT1, cysLT2 and GPR17 (Haeggstrom and Funk, 2011) . Previous studies have reported that LTs along with their cognate receptors are expressed in the brain, notably during HIV-1 infection (Basselin et al., 2011; Froldi et al., 1992; Matsuo et al., 1995) .
Astrocytic endfeet are directly in contact with the BBB and contribute in maintaining its integrity and homeostasis (Abbott et al., 2010) . Because astrocytes are the most abundant glial cells of the brain and are known to release elevated levels of different soluble factors including cysLTs, it is clear that these cells deserve special attention based on the frequency of HIV-1-mediated neurological complications. We thus assessed whether treatment of astrocytes with LTC 4 can result in production of soluble factors that modulate transmigration of HIV-1-infected primary human CD4 þ T cells across a BBB model. We demonstrate here that conditioned medium from LTC 4 -treated astrocytes enhances transmigration of HIV-1-infected CD4 þ T cells via CX3CL1/fractalkine production and promotes virus transfer to primary human macrophages.
Results
The cysLT 2 receptor is expressed on human astrocytes
We first verified by flow cytometry if human astrocytes express LTB 4 and/or cysLTs receptors. As illustrated in Fig. 1 , both the human astrocyticglioma U-87 MG cell line and primary normal human astrocytes (NHA) express high levels of cysLT2. However, no surface expression of the LTB 4 receptor could be detected on these cells (data not shown). Therefore, the following experiments were carried out with LTC 4 because it is considered as a potent cysLT found in the CNS. The less active cysLT metabolite N-Acetyl-LTE 4 (N-Ac-LTE 4 ), which is 100 times less potent than LTC 4 as a vasoconstricting agent (Foster et al., 1986) , was used as a control in our studies.
LTC 4 -treated astrocytes produce soluble factors that promote transmigration of HIV-1-infected CD4 þ T cells across BBB endothelial cells
The protective immunosurveillance of the CNS is ensured partly by CD4 þ T cells. HIV-1 can take advantage of this influx of leukocytes to invade the CNS based on the idea that CD4 þ T cells act as a major cellular reservoir for this retrovirus. Therefore, we set out to determine if soluble factors secreted by LTC 4 -treated astrocytes could modulate the mechanism of HIV-1 trafficking in the CNS. This goal was reached by performing experiments with the human cerebral microvascular endothelial cell line hCMEC/D3, which closely mimics most of the key characteristics of the BBB (Poller et al., 2008; Weksler et al., 2005) . Permeability assays using Blue Dextran showed that the barrier integrity of hCMEC/D3 monolayers grown on collagen-coated transwells (3 mm pore size) was preserved for at least 48 h following confluency (data not shown). Next, we tested the effect of astrocyte-conditioned medium on transmigration of primary human activated CD4 þ T cells, infected or not with HIV-1, across this BBB model. To this end, astrocyte-conditioned medium was harvested from U-87 MG astrocytic cells and NHA, which were either treated with LTC 4 , N-Ac-LTE 4 , or left untreated. The astrocyte-conditioned medium was placed in the lower chamber of the transwells. Finally, CD4 þ T cells infected or not with YU2, a brain-derived primary isolate of HIV-1 that utilizes CCR5 as a co-receptor, were placed in the upper chamber and transmigrated cells were quantified 24 h later. Preliminary experiments utilizing supernatants from human astrocytes treated with increasing doses of LTC 4 (i.e. 0.1, 1, 10 and 100 ng/ml) showed a statistically significant induction of CD4 T cell transmigration at 10 and 100 ng/ml, with a maximal effect at the highest concentration used (data not shown). Therefore, 100 ng/ml of LTC 4 was utilized for the following experiments. As depicted in Fig. 2A , astrocyte-conditioned medium from LTC 4 -treated U-87 MG cells induced a marked increase in transmigration of primary human CD4 þ T cells compared to media. Cell migration was not promoted when using astrocyte-conditioned medium from U-87 MG cells either left untreated or exposed to the less active analog N-Ac-LTE 4 . Interestingly, a comparable enhancement in cell transmigration mediated by conditioned medium from LTC 4 -treated U-87 MG cells was observed with both uninfected (left panel) and HIV-1-infected CD4 þ T cell cultures (right panel). Initial transmigration studies revealed that conditioned medium from LTC 4 -treated NHA was less powerful at promoting migration of CD4 þ T cells across hCMEC/D3 endothelial cells (data not shown). Hence, CD4 þ T cells were initially stained with the Calcein AM fluorescent dye prior to the transmigration assay in order to more efficiently quantify the lower numbers of transmigrated CD4 þ T cells. In agreement with our observations with U-87 MG cells, conditioned medium from LTC 4 -treated NHA attracted more CD4 þ T cells than conditioned medium from untreated astrocytes (Fig. 2B) . Again, treatment of astrocytes with the less active analog N-Ac-LTE 4 failed to induce any significant transmigration of CD4 þ T cells across BBB endothelial cells. In all these experiments, the β-chemokine RANTES was used as a positive control while culture medium (i.e. DMEM supplemented with 0.2% BSA) (called media) was used as a negative control for transmigration assays. The use of RANTES in the current work is þ T cells that had transmigrated in response to conditioned medium from U-87 MG cells either left untreated or treated with the listed stimuli. Virus production was monitored 9 days following coculture of MDMs and transmigrated CD4 þ T cells by quantifying the major viral core p24 protein, using an in-house ELISA assay. The measured p24 contents for each condition were as follows: 4.0 7 2.8 ng/mL (untreated), 11.4 76.3 ng/mL (LTC 4 ), 4.5 7 2.9 ng/mL (N-Ac-LTE 4 ), and 5.3 7 2.1 ng/mL (RANTES).
To compensate for donor-to-donor infection variations, the results shown represent the means 7 SD calculated from 3 independent experiments and are expressed as fold increase over media (A and B) or untreated cells (C) (Student t-test: n p o 0.05; compared to untreated cells).
founded on the notion that activated CD4 þ T cells are known to express CCR5 on their membrane (Monteiro et al., 2011) and also that this chemotactic agent is commonly used in cell transmigration assays (Desmetz et al., 2006; Kawai et al., 1999) . Importantly, attraction of CD4 þ T cells was not induced by media (DMEM/0.2% BSA) in which LTC 4 was added 24 h prior to the transmigration assay (data not shown), thus demonstrating that the observed augmentation in cell transmigration is not due to LTC 4 by itself but is linked with one or more soluble factor(s) secreted by LTC 4 -treated astrocytes. Perivascular macrophages are the first cells permissive to productive virus infection that circulating leukocytes infected with HIV-1 will meet after crossing the BBB. Therefore, in order to monitor the putative HIV-1 transfer from CD4 þ T cells to macrophages, MDMs were cocultured with HIV-1-infected CD4 þ T cells that had transmigrated in response to astrocyte-conditioned medium. As shown in Fig. 2C , MDMs produce more progeny virions when cocultured with CD4 þ T cells attracted by conditioned medium from LTC 4 -treated astrocytes compared to CD4 þ T cells that have transmigrated in response to conditioned medium from untreated or N-Ac-LTE 4 -treated astrocytes. We next verified if this higher HIV-1 transfer could be explained by a modulatory effect exerted by the astrocyte-conditioned medium from LTC 4 -treated cells on the virus infection levels of CD4 þ T cells. Although the astrocyte-conditioned medium did increase HIV-1 infection in CD4 þ T cells, possibly via some proinflammatory cytokines, viral production levels were the same for target cells exposed to conditioned medium from untreated, LTC 4 -, or N-Ac-LTE 4 -treated U-87 MG astrocytic cells (data not shown).
In parallel, we also tested whether astrocyte-conditioned medium could modulate the infectious potential of YU2 virions through the use of TZM-bl, an indicator cell line highly sensitive to HIV-1 infection. Our data did not reveal any modulation of virus infectivity following exposure of YU2 to conditioned medium from either untreated, LTC 4 -or N-Ac-LTE 4 -treated U-87 MG cells (data not shown). Therefore, it can be concluded that the enhanced virus production seen in MDMs results from a physical contact with a higher number of HIV-1-infected CD4 þ T cells that have transmigrated across the BBB model system in response to conditioned medium from LTC 4 -treated U-87 MG astrocytic cells.
A recent work has monitored the HIV-1 infection rate of CD4 þ T cells from peripheral blood and it was estimated that 0.06% and 0.14% of circulating CD4 þ T cells are infected with HIV-1 during early and chronic infection, respectively (Josefsson et al., 2011) . Therefore, we next set out to determine whether cells productively infected with HIV-1 and uninfected bystander cell populations (i.e. Neighboring uninfected cells exposed to soluble factors released by virus-infected cells) were attracted differently by conditioned medium from LTC 4 -treated U-87 MG cells. To achieve this goal, activated CD4 þ T cells were first infected with fully infectious R5-tropic reporter viruses that encode for a cell surface molecule called the murine heat-stable antigen (HSA/CD24) (used as a reporter molecule). This unique tool permits to discriminate between cells productively infected with HIV-1 (i.e. HSA þ ) and uninfected bystander cells (i.e. HSA À ) on the basis of HSA/CD24 surface expression. The mean percentage of activated CD4 þ T cells productively infected using this reporter virus was 5.3%, which is in agreement with our previous observations (Imbeault et al., 2009a (Imbeault et al., , 2009b . The percentage of HIV-1-infected CD4 þ T cells, as monitored by HSA expression, was lower in the total cell population attracted by conditioned medium from LTC 4 -stimulated astrocytes (3.2%) than with conditioned medium from untreated (4.9%) or N-Ac-LTE 4 -treated astrocytes (5.6%) (Fig. 3A) . A diminished transmigration of CD4 þ T cells productively infected with HIV-1 was also seen when using RANTES (3.6%). However, even though the percentage of HIV-1-infected CD4 þ T cells is lower in the transmigrated cell population in response to conditioned medium from LTC 4 -treated astrocytes, the total number of virusinfected CD4 þ T cells (i.e. HSA þ ) that have been attracted across our BBB model is still higher when using such astrocyteconditioned medium (Fig. 3B ).
LTC 4 does not induce BBB disruption by increasing MMP-2 or MMP-9 production by astrocytes
It has been reported that astrocytes produce MMPs, which can ultimately disrupt the BBB by degrading tight junction proteins (Gramegna et al., 2011; Ivey et al., 2009 ). Of these, MMP-2 and MMP-9, known to be produced by astrocytes, are often found in the CNS of HIV-1-infected individuals and it was postulated that they might play a key role in BBB disruption (Feng et al., 2011; Qiu et al., 2011; Yang et al., 2007) . We thus tested whether LTC 4 treatment induces a deregulation of MMP-2 and MMP-9 secretion by astrocytes. Zymography assays revealed that both U-87 MG cells and NHA produce MMP-2 but not MMP-9 (Fig. 4A) . Nonetheless, LTC 4 did not increase MMP-2 secretion by astrocytes nor did it induce any MMP-9 production. In accordance with these results, conditioned medium from LTC 4 -stimulated astrocytes failed to significantly increase the passage of a 70-kDa dextranconjugated fluorescent dye through hCMEC/D3 monolayers ( Fig. 4B) , suggesting a lack of effect on BBB integrity. To better determine if the more robust transmigration of CD4 þ T cells induced by conditioned medium from LTC 4 -stimulated astrocytes does not depend on the disruption of the in vitro BBB, chemotaxis experiments were performed using collagen-coated transwells but this time in absence of hCMEC/D3 cells. The results obtained from the chemotaxis assays using such transwells showed a similar effect of LTC 4 -treated astrocyte conditioned medium, although with a much higher absolute number of transmigrated cells than in the presence of a hCMEC/D3 monolayer (data not shown), which suggest that BBB disruption does not play a significant role in the increased transmigration of CD4 þ T cells induced by conditioned medium from LTC 4 -treated astrocytes.
CX3CL1/fractalkine is involved in the LTC 4 -mediated increase in transmigration of CD4 þ T cells
We next set out to shed light on the LTC 4 -mediated soluble factor(s) produced by human astrocytes that can drive transmigration of CD4 þ T cells across BBB endothelial cells. Since cysLTs have been shown to induce IL-8 production in different cell types (Rola-Pleszczynski and Stankova, 2007) and IL-8 acts as a potent Tcell chemoattractant, we initially tested whether astrocytes could secrete IL-8 upon treatment with LTC 4 . In our hands, LTC 4 failed to induce IL-8 secretion by astrocytes as opposed to TNFα and IFNγ that were used as positive controls in this series of investigations (data not shown). Thereafter, mRNA expression of several known chemotactic molecules for CD4 þ T cells (i.e. IP-10/CXCL10, MCP-1/ CCL2, MCP-2/CCL8, MCP-4/CCL13, MIP-1α/CCL3, MIP-3/CCL20, SLC/ CCL21, RANTES/CCL5, PARC/CCL18, TARC/CCL17 and fractalkine/ CX3CL1) was measured by quantitative real-time polymerase chain reaction (qRT-PCR) in U-87 MG cells following LTC 4 treatment. Among these chemokines, only fractalkine/CX3CL1 showed a significant increase (4-fold) in mRNA expression in LTC 4 -treated U-87 MG cells (Fig. 5A ). To directly assess the implication of this chemokine in the increased chemotactic potential of conditioned medium from LTC 4 -treated astrocytes, we tested if a CX3CL1/ fractalkine blocking antibody could neutralize this phenomenon. Data shown in Fig. 5B indicate that a CX3CL1/fractalkine blocking antibody, but not an isotype-matched irrelevant control antibody, reduces significantly the increased transmigration of HIV-1-infected CD4 þ T cells in response to conditioned medium from LTC 4 -treated U-87 MG cells (i.e. a reduction of 37.5 715%). The blocking antibody causes a comparable diminution when using conditioned medium from TNFα-and IFNγ-treated U-87 MG cells, which corroborates the importance of CX3CL1/fractalkine in the increased transmigration of CD4 þ T cells. To validate further the role of CX3CL1/fractalkine in the more important cell migration across the BBB experimental model system, we achieved gene silencing using RNA interference (RNAi) technology. As depicted in Fig. 6A , CX3CL1/fractalkine mRNA expression is efficiently attenuated in U-87 MG cells following transfection of a pool of four specific small interfering RNAs (siRNAs). Importantly, culture medium from LTC 4 -treated astrocytes in which CX3CL1/fractalkine mRNA expression has been reduced could no longer increase the transmigration of HIV-1-infected CD4 þ T cells across our BBB model (Fig. 6B) . Overall, these results indicate that the LTC 4 -dependent secretion of CX3CL1/fractalkine by human astrocytes is responsible for the enhanced transmigration of HIV-1-infected CD4 þ T cells through an in vitro model of BBB.
Discussion
It has been proposed that HIV-1 can invade the CNS via virusinfected monocytes and CD4 þ T cells that cross the BBB (FischerSmith et al., 2001; Glass et al., 1995; Haas et al., 2000 Haas et al., , 2003 Harrington et al., 2005; Persidsky et al., 1999; Schnell et al., 2011; Wang et al., 2008 2008; Weksler et al., 2005; Zhao et al., 2011) . In corollary, our results indicate that the cysLT2 receptor is highly expressed on human astrocytes (both a continuous cell line/U-87 MG and primary cells/NHA). As for cysLTs, they have been detected in the cerebrospinal fluid (CSF) of HIV-1-infected individuals (Froldi et al., 1992 (Froldi et al., , 1995 Genis et al., 1992) , and they are also present in infected brain tissues or virus-infected CNS cell types (Basselin et al., 2011; Froldi et al., 1992 Froldi et al., , 1995 Genis et al., 1992; Maccarrone et al., 2000) .
We investigated whether treatment of human astrocytes by cysLTs could mediate production of soluble factor(s) that can in turn affect transmigration of HIV-1-infected CD4 þ T cells across an in vitro BBB model. Along with LTD 4 , LTC 4 is known to be one of the most potent cysLTs. Therefore, we used only LTC 4 to stimulate astrocytes since all cysLTs engage the same receptors. We report here that conditioned medium from LTC 4 -treated astrocytes induces a more potent transmigration of HIV-1-infected CD4 þ T cells across BBB endothelial cells than supernatants from untreated astrocytes. The LTC 4 -mediated enhancement in cell transmigration was seen when using a final concentration of LTC 4 (i.e. 100 ng/ml) that is somewhat higher than what is measured in brains of HIV-1 transgenic rats or found in CSF obtained from HIV-1-infected individuals (Basselin et al., 2011; Froldi et al., 1992 Froldi et al., , 1995 (Pal and Grover, 1983) . The possibility that a fibroblast contamination in NHA might act as a confounding factor is fully supported by the demonstrated capacity of LTC 4 to modulate some fibroblast functions (Medina et al., 1994; Phan et al., 1988) , which in turn could affect the biology of astrocytes. Moreover, it has been reported that fibroblast cells can express CX3CL1/fractalkine under different experimental conditions (Husberg et al., 2008; Isozaki et al., 2011; Jones et al., 2013; Ohta et al., 2010) . As reviewed previously, CX3CL1/fractalkine has been proposed to play a pivotal role in spreading of HIV-1 infection in the organism via virus-infected lymphocytes (Becker, 2007; Cotter et al., 2002) . Our data suggest that CX3CL1/fractalkine production by astrocytes induced by the cysLTs LTC 4 may also play an important role in the HIV-1 neuroinvasion. Nevertheless, chemotaxis of CD4 þ T cells is known to be induced by many other chemokines, lipid mediators and interleukins. Additional studies are needed to determine whether another yet-to-be defined soluble factor is produced by LTC 4 -treated astrocytes which may also promote transmigration of HIV-1-infected CD4 þ T cells across BBB endothelial cells. Since activated CD4 þ T cells are known to be highly permissive to HIV-1 infection, attraction of this cell population in the CNS by LTC 4 -stimulated astrocytes may provide a renewed source of target cells thus allowing a sustained viral replication in this body compartment. We also provide evidence that the increased numbers of CD4 þ T cells attracted across the BBB give rise to a more potent infection in trans of macrophages, which constitute a stable viral reservoir that facilitate spread of HIV-1. Therefore, it can be speculated that stimulation of human astrocytes with cysLTs such as LTC 4 induces neuroinvasion and a sustained viral replication in the CNS via a possible HIV-1 transfer to perivascular macrophages. It is of interest to note that our data suggest also that conditioned medium from LTC 4 -treated astrocytes attracts both uninfected bystander cells and CD4 þ T cells productively infected with HIV-1 with a slightly higher efficiency for the former cell population. It is possible that a fraction of HIV-1-infected CD4 þ T cells become less responsive to subsequent stimulation by the chemotactic molecule CX3CL1/fractalkine, or yet again found to be in an anergic state rendering them unable to efficiently transmigrate (Wherry, 2011) . It has been reported previously that HIV-1 infection of leukocytes induces a better transmigration across the BBB in response to the chemokine CCL2, due to an increased expression of CCR2 (Eugenin et al., 2006) . These data suggest that such virus-infected cells do not lose their inherent ability to transmigrate at least in response to CCL2. It is possible that HIV-1-infected CD4 þ T cells do not respond as well to CX3CL1/ fractalkine. The explanation for this discrepancy is currently unknown but it should be stated that the experimental procedure performed by Eugenin et al. (2006) does not permit to discriminate between migration of uninfected bystander cells versus HIV-1-infected leukocytes. Nonetheless, flow cytometric analyses of the CX3CL1/fractalkine receptor CX3CR1 indicate that it is expressed on CD4 þ T cells that transmigrate in our assay. However, its surface expression level is comparable in transmigrated HIV-1-infected CD4 þ T cells upon exposure to culture medium from human astrocytes either left untreated or treated with LTC 4 or N-Ac-LTE 4 (data not shown). It can be concluded that CX3CL1/ fractalkine does not seem to modulate its cell surface receptor CX3CR1 level at least in transmigrating HIV-1-infected CD4 þ T cells. Furthermore, we found that MMP-2 but not MMP-9 is produced by human astrocytes, and that LTC 4 does not stimulate secretion of MMP-2. In addition, LTC 4 treatment does not induce any alteration of the barrier integrity of hCMEC/D3 monolayer. The neuroinvasion of HIV-1 via CD4 þ T cells in response to conditioned medium from LTC 4 -stimulated astrocytes is thus independent of a BBB disruption caused by gelatin-binding MMPs. Several studies have suggested that MMP activity is an important mediator involved in the BBB disruption seen in HIV-1-carrying patients showing neurological disorders, and HIV-1 particles and viral proteins (e.g. Tat and gp120) were shown to induce expression of MMP-2 and MMP-9 in astrocytes (Ivey et al., 2009; Louboutin et al., 2010 Louboutin et al., , 2011 . We can thus propose a model for HIV-1-related neuropathology in which physical damages to the BBB are mostly caused by the virus itself, whereas cysLTs such as LTC 4 participate to the neuroinvasion process by inducing the secretion of CX3CL1/fractalkine and other chemotactic molecules by astrocytes. Of course, further investigations will be needed to establish the possible implications of the astrocyte secretome induced by LTC 4 on a more physiological BBB model which would be also sheeted by perivascular macrophages and pericytes. Indeed, infection of astrocytes by HIV-1 was shown to compromise BBB integrity through endothelial apoptosis, misguided astrocyte endfeet and dysregulation of lipoxygenase/cyclooxygenase (Eugenin et al., 2011) . Analyzing the effect of LTC 4 on the astrocyte-BBB relationship in the context of HIV-1 infection would shed light on the more precise mechanism(s) governing neuroinvasion and neuropathology processes.
Conclusions
Our results underline the complex interplay between neuroinvasion and neuroinflammation in the context of HIV-1 infection. The sustained prevalence of neurological complications that arise in virus-infected individuals is intimately linked to the neuroinflammation processes induced by HIV-1. Eicosanoids (such as LTs and prostaglandins) -which are normally produced under pathological conditions -are known to negatively modulate HIV-1 infection in different cell types including some of which are found in the CNS (Bertin et al., 2012) . On the other hand, we show herein that cysLTs, produced in the CNS of infected individuals, can activate astrocytes and promote the neuroinvasion of HIV-1. In vivo experiments with non-human primates should be considered to better understand the overall contribution of LTs in the neuropathogenesis of HIV-1 infection.
Materials and methods

Antibodies and reagents
LTC 4 and its less active metabolite N-Acetyl-LTE 4 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Surface expression of LT receptors was determined by flow cytometry using either a rabbit anti-cysLT2 antibody (Cayman Chemical) followed by a goat anti-rabbit antibody conjugated with Alexa Fluor s 488 (Molecular Probes, Burlington, Ont., Canada) or a biotinylated anti-BLT1 antibody (Cayman Chemical) followed by a streptavidin-R-phycoerythrin (BD Bioscience, Mississauga, Ont., Canada). Productive HIV-1 infection of primary human CD4 þ T cells with fully competent HSA-encoding reporter virus (see below for more details) was assessed by flow cytometry using the R-phycoerythrin conjugated anti-HSA/CD24 antibody obtained from BD Bioscience (Mississauga, Ont., Canada). The R-phycoerythrin conjugated anti-CX3CR1 and its isotype-matched control antibody were purchased from Biolegends (San Diego, CA, USA). The anti-CX3CL1/fractalkine blocking antibody was purchased from R&D Systems (Minneapolis, MN, USA). IL-8 was quantified using the BD Biosciences Human IL-8 ELISA Set. High glucose DMEM and RPMI-1640 media were purchased from Wisent Bioproducts (Montréal, Que., Canada). Macrophage colony-stimulating factor (M-CSF) was purchased from GenScript Corporation (Piscataway, NJ, USA). Primers for PCR were purchased from Integrated DNA Technologies (San Diego, CA, USA). ThinCerts transwells (3.0 mm pore size) were purchased from Greiner Bio-One (Frickenhausen, BadenWürttemberg, Germany). Purified IFNγ and TNFα were obtained from Biolegend (San Diego, CA, USA). Bovine serum albumin (BSA) (20% sterile and filtered solution) was purchased from Wisent Bioproducts. All culture flaks and plates were purchased from BD Biosciences. Collagen and Blue Dextran (MW: 70 kDa) were purchased from Sigma Aldrich (St. Louis, MO, USA). Calcein AM was obtained from Invitrogen (Burlington, Ont., Canada), lithium chloride (LiCl) was purchased from EMD chemicals (Gibbstown, NJ, USA), whereas Dextran-Rhodamine fluorescent dye (70 kDa) and Lipofectamine ™ RNAiMAX transfection reagent were purchased from Life Technologies (Carlsbad, CA, USA).
Plasmids pYU2 is a macrophage/CCR5-tropic HIV-1 molecular clone isolated directly from human brain (obtained through the NIH AIDS Research and Reference Reagent Program, Germantown, MD,USA) (Li et al., 1991) . The infectious molecular clone pNL4-3Bal-IRES-HSA was recently described (Imbeault et al., 2009a) . Briefly, besides encoding all HIV-1 proteins and producing R5 (Bal)-tropic virions, this NL4-3-based vector additionally codes for the cell surface murine heat-stable antigen (HSA)/CD24, enabling for efficient early identification of cells productively infected with HIV-1.
Cell culture
The human glioblastoma-astrocytoma, epithelial-like cell line U-87 MG was obtained from the American Type Culture Collection (ATCC HTB-14, Manassas, VA, USA). NHA were purchased from Lonza (Walkersville, MD, USA). In order to obtain astrocyteconditioned medium (additional details can be found in following section entitled "Transmigration assay"), NHA were cultured in astrocyte basal medium supplemented with astrocyte growth medium (Lonza). Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated by Ficoll-Hypaque gradient (Wisent Inc., St-Bruno, QC, Canada). Next, PBMCs were plated at a final concentration of 1 Â 10 7 cells/ml in 75 cm 2 flasks (BD Biosciences) for 2 h in order to separate by adherence monocytes from the other non-adherent cells. After washing with endotoxin-free phosphate-buffered saline (PBS) (Sigma-Aldrich), monocytes were cultured in complete RPMI-1640 medium (that is RPMI-1640 supplemented with 5% heat-inactivated autologous serum, 100 U/ml penicillin G and 100 μg/ml streptomycin) in the presence of M-CSF (10 ng/ml) for 6 days to obtain primary human monocyte-derived macrophages (MDMs). Cells were then recovered with a soft cell scraper and plated in 24-well plates at a final concentration of 1 Â 10 5 cells per well in RPMI-1640 medium supplemented with 5% autologous serum. Non-adherent cells obtained from the same donors were used to isolate CD4 þ T cells by a negative selection process using the EasySep CD4 þ T cell enrichment kit (Vancouver, BC, Canada). Cells were then activated with the mitogenic agent PHA-L (1 mg/ml) for 3 days prior their use and maintained in complete RPMI-1640 culture medium supplemented with recombinant human IL-2 (30 U/ml) at a density of 2 Â 10 6 cells/ml. Human embryonic kidney (HEK) 293T
(ATCC) and TZM-bl cells (NIH AIDS Research and Reference Reagent Program) were cultured in complete Dulbecco's modified Eagle's medium (DMEM), which was supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin G and 100 μg/ml streptomycin. The immortalized human cerebral microvascular endothelial cell line hCMEC/D3, which has been shown to constitutively express many endothelial and/or BBB markers with the appropriate subcellular localization pattern, was maintained in culture as described previously (Poller et al., 2008; Weksler et al., 2005) . The hCMEC/D3 cell line was a generous gift from Dr. Couraud (Institut Cochin, France) under the license from the Institut National de la Santé et de la Recherche Médicale (INSERM, Paris, France).
Virus production
Viruses were produced by the calcium phosphate coprecipitation method in 293T cells as described previously (Fortin et al., 1997) . In brief, 293T cells were transiently transfected with pYU2 and pNL4-3Bal-IRES-HSA to produce fully infectious R5-tropic HIV-1 particles and fully competent HSA-encoding reporter virions, respectively. Virus preparations were normalized for virion content by using an in-house enzymatic assay specific for the major viral p24 protein. In this test, two distinct monoclonal anti-p24 antibodies (i.e. 183-H12-5C and 31-90-25) are used in combination to quantify p24 levels (Bounou et al., 2002) . In addition, the infectivity of our virus stocks was assessed using TZM-bl indicator cells. This cell line is a genetically modified HeLa derived cell line expressing large amounts of cell surface CD4, CCR5 and CXCR4 (Steckbeck et al., 2005) . These cells carry separate integrated copies of the luciferase and β-galactosidase genes under the control of the HIV-1promoter and are highly susceptible to infection with different variants (both R5-and X4-tropic). Virus preparations that did not allow sufficient reporter gene activity were discarded. could be observed by microscopy (data not shown). Cell-free supernatants from MDMs were harvested 9 days post-infection to quantify trans infection levels. Virus production was estimated by measuring p24 levels in cell-free culture supernatants by ELISA.
HIV-1 infection
Flow cytometry analysis
Before staining, cells were incubated for 15 min at 4 1C in PBS containing 0.1% sodium azide, 10% heat-inactivated human fibrindepleted plasma, 10% normal goat serum (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and 10% FBS to block non-specific binding sites and washed once with PBS containing 0.1% sodium azide and supplemented with 5% FBS. To monitor cell surface expression of LT receptors and CX3CR1, cells were incubated with specific antibodies or with an appropriate isotypematched irrelevant control antibody (for non-specific staining) for 30 min at 4 1C. Cells were then washed with PBS supplemented with 0.1% sodium azide and 5% FBS and fixed in a 2% paraformaldehyde solution before analysis by flow cytometry (Epics ELITE ESP; Coulter Electronics).
Quantitative real-time polymerase chain reaction
For detection and quantification of CX3CL1/fractalkine mRNA (sense: GCAGCCTCACAGTCCTTACC; antisense: GTCTCTGCTCTGC-CCATTTC), cells were either left untreated or treated for 4 h before extracting total RNA which was purified utilizing the illustraRNAspin RNA isolation kit (GE Healthcare life sciences, Piscataway, NJ, USA). cDNAs were generated with the Moloney murine leukemia virus (M-MLV) reverse transcriptase and random primers as indicated by the manufacturer (Invitrogen). Amplification of cDNA was achieved using the SYBR Green PCR Master Mix (Life Technologies). To ensure quantification precision, all real-time PCR amplified samples were normalized using the 18S housekeeping gene (sense: TAGAGGGA-CAAGTGGCGTTC; antisense: CGCTGAGCCAGTCAGTGT). The cycling conditions used for the Applied Biosystems 7500 sequence detection system included a hot start (50 1C for 2 min and 95 1C for 10 min), followed by 40 cycles of denaturation (95 1C for 15 s) and extension (63 1C for 1 min) with end point acquisition.
Zymography assay
Gelatin zymography was performed as described previously with slight modifications (Hu and Beeton, 2010) . In brief, U-87 MG astrocytic cells and NHA were cultured in 6 well plates (3.5 Â 10 5 cells per well) for 24 h. Next, cells were either left untreated or treated with LTC 4 or N-Ac-LTE 4 (100 ng/ml). Forty-eight hours post-stimulation, culture medium for astrocytes (mock) or filtered astrocyteconditioned medium was mixed with an equal volume of 2 Â zymography buffer (125 mM Tris hydrochloride [pH 6.8], 4% sodium dodecyl sulfate (SDS), 20% glycerol and 0.25% bromophenol blue). Then, samples were electrophoresed on a 10% (w/v) polyacrylamide gel containing 0.1% (w/v) gelatin (MP Biomedicals, Solon, OH, USA). After electrophoresis, the gel was washed for 30 min with 1 Â renaturating buffer (Novex s Zymogram from Invitrogen, Burlington, Ont., Canada) followed by 30 min incubation with 1 Â developing buffer (Novex s Zymogram) with gentle shaking. After an overnight incubation with a fresh solution of developing buffer at 37 1C, gels were rinsed, stained for 1 h in Coomassie Brilliant Blue solution (Bio-Rad laboratories, Mississauga, Ont., Canada), and then destained in a 10% acetic acid and 30% methanol solution.
Transmigration assay
First, hCMEC/D3 cells were cultured in collagen-coated ThinCerts transwells (12 Â 10 3 per transwell) for 7 days in complete EBM-2 culture medium in presence of 10 mM LiCl. To obtain astrocyteconditioned media, U-87 MG astrocytic cells or NHA were plated in 6 well plates (3.5Â 10 5 per well) in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin G and 100 μg/ml streptomycin. One day after, cells were washed and stimulated with LTC 4 or N-Ac-LTE 4 (100 ng/ml) in DMEM/0.2% BSA or left untreated for 24 h, before harvesting cell-free supernatants. PHA-activated primary human CD4 þ T cells either left uninfected or infected with HIV-1 were resuspended in DMEM/0.2% BSA at a density of 20 Â 10 6 cells/ml. Next, cells were overlayed on transwells (5 Â 10 5 per transwell). Alternatively, CD4 þ T cells were stained with the Calcein AM fluorescent dye (10 mM) for 30 min and then thoroughly washed before being resuspended prior to transmigration. Thereafter, filtered astrocyteconditioned medium (0.65 ml) was placed in the lower chamber. After 24 h, transmigrated CD4 þ T cells were either counted by flow cytometry or quantified by fluorometry at 460/520 nm (MLX microtiter luminometer, Dynex Technologies, Chantilly, VA, USA).
siRNA silencing of CX3CL1/fractalkine U-87 MG were plated 24 h before transfection in 6 well plates (3 Â 10 5 cells/well) in 2.5 ml of DMEM medium supplemented with 10% heat-inactivated FBS without antibiotics. Cells were transfected with 10 pmoles of CX3CL1/fractalkine-specific siRNA (siGENOMESMARTpool, Thermoscientific Dharmacon) or nontargeting siRNA (AllStars Negative Control, Qiagen) using Lipofectamine RNAiMAX as indicated by the manufacturer (Invitrogen). Cells were washed at 24 h after transfection and cultured in fresh media (DMEM/10% FBS without antibiotics). Forty-height hours after transfection, astrocytes were either left untreated or stimulated with 100 ng/ml of LTC 4 or N-Ac-LTE 4 for 24 h. Cells were then lysed for CX3CL1/fractalkine mRNA quantification and supernatants were utilized for transmigration experiments.
Statistical analysis
All experiments were repeated at least three times with different donors for CD4 þ T cells and MDMs, and each figure combines the results obtained with all the different donors unless otherwise specified. The statistical significance of the difference between groups was determined using the Student t-test. Calculations were made with Prism version 3.03 (GraphPad Software Inc., La Jolla, CA, USA). The P valueso0.05 were considered statistically significant. 
